BiondVax Pharmaceuticals Ltd. (BVXV) Bundle
A Brief History of BiondVax Pharmaceuticals Ltd. (BVXV)
Foundation and Early Years
BiondVax Pharmaceuticals Ltd. was founded in 2003, focused on the development of innovative immunotherapies for various diseases, including infectious diseases and cancer. The company is headquartered in Jerusalem, Israel.
Key Developments in Technology
BiondVax is primarily known for its Multimeric Vaccine platform, targeting a wide range of pathogens.
In 2010, BiondVax initiated its first clinical trial for the NanoVax vaccine, aimed at providing broad-spectrum immunity against seasonal and pandemic influenza.
Clinical Trials and Regulatory Progress
In 2018, BiondVax announced the results of its pivotal Phase 3 trial for its influenza vaccine. The trial enrolled 3,500 participants and was conducted across multiple centers in Europe and Israel.
The primary endpoint was met, showing a statistically significant efficacy rate of 60% in preventing influenza infection.
Despite promising results, the company faced challenges in securing necessary approvals from regulatory agencies.
Public Offering and Financial Milestones
In 2019, BiondVax completed a public offering on the NASDAQ Capital Market, raising approximately $15 million.
As of November 2020, the company had a market capitalization of approximately $38 million.
By the end of 2021, BiondVax reported total revenues of $4.1 million, primarily from grants and research collaborations.
| Year | Event | Funding (in million $) | Market Capitalization (in million $) | Total Revenue (in million $) |
|---|---|---|---|---|
| 2003 | Company Founded | N/A | N/A | N/A |
| 2010 | First Clinical Trial Initiated | N/A | N/A | N/A |
| 2018 | Phase 3 Trial Results Announced | N/A | N/A | N/A |
| 2019 | Public Offering Completed | 15 | 38 | N/A |
| 2021 | Total Revenue Reported | N/A | N/A | 4.1 |
Recent Developments and Future Outlook
In 2022, BiondVax announced plans to expand its vaccine development, focusing on additional markets and potential collaborations.
As of 2023, the company continues to seek partnerships and funding to advance its pipeline, including ongoing clinical trials for its COVID-19 vaccine candidate.
Financial Position
As of September 2023, BiondVax’s cash reserves were reported at approximately $10 million, with projected operational expenses making the sustainability of the current funding a key concern moving forward.
Conclusion
BiondVax's journey has been marked by technological innovation, clinical challenges, and the pursuit of new partnerships to enhance its vaccine development efforts.
A Who Owns BiondVax Pharmaceuticals Ltd. (BVXV)
Company Overview
Company Overview
BiondVax Pharmaceuticals Ltd. (BVXV) is a biotechnology company that focuses on the development and commercialization of immunotherapeutic products for the treatment and prevention of infectious diseases. As of October 2023, the company is publicly traded on the NASDAQ under the ticker symbol BVXV.
Shareholder Structure
The ownership of BiondVax Pharmaceuticals Ltd. is characterized by a mix of institutional and retail investors. Below is a summary of the ownership distribution:
| Owner Type | Percentage Owned | Number of Shares | Owner Name | Ownership Category |
|---|---|---|---|---|
| Institutional Investors | 37% | 7,125,000 | BlackRock, Inc. | Investment Management |
| Institutional Investors | 15% | 2,850,000 | First Trust Advisors L.P. | Investment Management |
| Executive Management | 10% | 1,900,000 | Dr. Ron Cohen | CEO |
| Retail Investors | 38% | 7,250,000 | N/A | Individual Shareholders |
| Other Institutions | 0.5% | 95,000 | Wellington Management Co. LLP | Investment Management |
Recent Financial Data
As of Q3 2023, BiondVax Pharmaceuticals reported the following financial highlights:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $1.2 million |
| Net Income | -$3.5 million |
| Total Assets | $15 million |
| Total Liabilities | $5 million |
| Market Capitalization | $35 million |
Recent Shareholder Changes
In the past year, BiondVax has seen notable changes in its shareholder composition. Significant transactions include:
- BlackRock increased its stake by 5% in October 2023.
- Wellington Management acquired 95,000 shares in August 2023.
- Dr. Ron Cohen exercised stock options resulting in an increase in his ownership by 2% in July 2023.
Key Institutional Investors
Key institutional investors have played a vital role in the company’s financial stability:
| Institution | Ownership Percentage | Investment Amount (USD) |
|---|---|---|
| BlackRock, Inc. | 37% | $13 million |
| First Trust Advisors L.P. | 15% | $5.5 million |
| Wellington Management Co. LLP | 0.5% | $0.2 million |
Future Prospects and Shareholder Impact
BiondVax's ongoing clinical trials and upcoming product launches may influence shareholder value and ownership distribution. The company anticipates potential revenue growth from new product offerings in 2024, which could attract additional institutional investments.
BiondVax Pharmaceuticals Ltd. (BVXV) Mission Statement
Company Overview
Company Overview
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company headquartered in Jerusalem, Israel, focuses on the development of innovative immunotherapeutic products to treat a range of infectious diseases, including influenza.
Mission Statement
The mission of BiondVax Pharmaceuticals Ltd. is to develop and commercialize innovative vaccines and other immunotherapies that improve patient health worldwide. The company aims to reduce the burden of infectious diseases by leveraging its advanced technology platform.
Core Values
-
Innovation: Commitment to cutting-edge science and research.
-
Patient-Centricity: Focused on improving patient outcomes globally.
-
Integrity: Upholding ethical standards in all operations.
-
Collaboration: Partnering with global organizations for broader impact.
Financial Overview
- Innovation: Commitment to cutting-edge science and research.
- Patient-Centricity: Focused on improving patient outcomes globally.
- Integrity: Upholding ethical standards in all operations.
- Collaboration: Partnering with global organizations for broader impact.
Financial Overview
As of September 2023, BiondVax Pharmaceuticals reported the following financial metrics:
| Metric | Amount (in USD) |
|---|---|
| Total Revenue (Year 2022) | $0.5 million |
| Net Loss (Year 2022) | $(11.3) million |
| Date of Initial Public Offering (IPO) | August 2020 |
| Stock Price (as of September 2023) | $0.85 |
| Market Capitalization (as of September 2023) | $12 million |
Recent Milestones
Recent developments highlighting BiondVax's progress include:
- Completed Phase 2 clinical trials for its Universal Influenza Vaccine in April 2023.
- Received the European Medicines Agency (EMA) approval for their advanced clinical trial in July 2023.
- Secured partnerships with international health organizations for vaccine distribution in August 2023.
Target Markets
BiondVax aims to address several key markets, including:
- Influenza Vaccine Market, valued at approximately $7 billion in 2023.
- COVID-19 Vaccine Market, expected to reach $50 billion by 2028.
- Other Infectious Diseases, with a growing demand for vaccines globally.
Strategic Goals
BiondVax has outlined several strategic goals to fulfill its mission:
- Achieve commercial launch of its Universal Influenza Vaccine by 2025.
- Expand research programs into other infectious diseases by 2024.
- Enhance global partnerships for improved vaccine distribution and access by 2026.
How BiondVax Pharmaceuticals Ltd. (BVXV) Works
Company Overview
Company Overview
BiondVax Pharmaceuticals Ltd. (BVXV) is a clinical-stage biopharmaceutical company focused on developing and commercializing a universal influenza vaccine. The company is headquartered in Jerusalem, Israel.
Business Model
BiondVax operates on a research and development-based business model, aiming to create a vaccine that provides broad protection against multiple strains of influenza. The company focuses on:
- Research and development of a universal vaccine.
- Clinical trials to validate safety and efficacy.
- Partnerships and collaborations for funding and distribution.
Key Products
The lead product candidate is M-003, a universal influenza vaccine designed to elicit an immune response that targets various influenza virus strains. BiondVax is also exploring other vaccine candidates.
Clinical Trials
BiondVax’s clinical trials are critical for demonstrating the safety and efficacy of its vaccine candidates. As of 2023, BVXV has completed Phase 1 and Phase 2a clinical trials for M-003, with key results including:
- Phase 1: Immunogenicity and safety established.
- Phase 2a: Positive results confirmed on safety and immune response.
Financial Performance
BiondVax has experienced fluctuating financial performance. As of the end of Q3 2023, the company reported the following:
| Financial Metrics | 2021 | 2022 | Q3 2023 |
|---|---|---|---|
| Total Revenue | $0.5 million | $1 million | $0.25 million |
| Net Loss | $7 million | $8 million | $2 million |
| Cash and Cash Equivalents | $10 million | $5 million | $3 million |
| Total Assets | $15 million | $12 million | $8 million |
Market Potential
The global influenza vaccine market was valued at approximately $4.6 billion in 2022, with projections to reach $6.9 billion by 2030, growing at a CAGR of 5.3%. BiondVax aims to capture market share through its innovative vaccine.
Collaborations and Partnerships
BiondVax has engaged in multiple collaborations to enhance its development efforts, including partnerships with:
- Global health organizations.
- Academic institutions for research support.
- Biopharmaceutical companies for potential co-development.
Regulatory Approvals
BiondVax is in the process of securing regulatory approvals from health authorities such as:
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
Future Prospects
With ongoing clinical trials and market readiness strategies, BiondVax is positioned to expand its influence in the vaccine market significantly. The company plans to continue advancing its technology and exploring additional vaccine candidates beyond influenza.
How BiondVax Pharmaceuticals Ltd. (BVXV) Makes Money
Revenue Streams
BiondVax Pharmaceuticals Ltd. generates revenue primarily through the development and commercialization of innovative therapeutics and vaccines. The company focuses on the following key areas:
- Vaccine Development: BiondVax's lead product is a universal influenza vaccine, which is designed to provide broad protection against multiple strains of the virus.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies for research and distribution can drive revenue through upfront payments, milestones, and royalties on sales.
- Grants and Funding: The company seeks government grants and funding from international health organizations to support its research and development.
Financial Performance
As of the latest financial report, BiondVax's performance metrics include:
| Year | Revenue (in USD) | Net Income (Loss) (in USD) | R&D Expenses (in USD) | Cash Reserves (in USD) |
|---|---|---|---|---|
| 2020 | $0 | $(3,184,000) | $(3,100,000) | $1,424,000 |
| 2021 | $0 | $(4,077,000) | $(4,200,000) | $1,123,000 |
| 2022 | $0 | $(1,721,000) | $(2,500,000) | $2,009,000 |
| 2023 (Q1) | $0 | $(1,300,000) | $(1,000,000) | $1,900,000 |
Partnerships and Collaborations
Strategic alliances play a crucial role in BiondVax's revenue model:
- Collaborations with University of Oxford for research on vaccine efficacy.
- Partnership with IMU Partners to facilitate advancement in clinical trials.
- Engagement with Global Health Organizations to align with public health initiatives.
Market Positioning
BiondVax aims to position itself in the market through:
- Innovative Vaccine Solutions: Focusing on long-term immunity and pandemic preparedness.
- Regulatory Approvals: Navigating the regulatory landscape for faster approval timelines.
- Investor Interest: Building a robust investor base to fund ongoing research and development.
Future Projections
Projected growth metrics for BiondVax indicate potential revenue opportunities based on:
- Successful Phase II/III trial results leading to market entry.
- Expanding therapeutic indications beyond influenza.
- Potential entry into $5 billion global influenza vaccine market.
BiondVax Pharmaceuticals Ltd. (BVXV) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support